BRIEF-Shanghai Shen Lian Says Phase II Clinical Trial Of UB-221 Meets Primary Endpoint

2

Sept 20 (Reuters) – Shanghai Shen Lian Biomedical Corp : * SAYS PHASE II CLINICAL TRIAL OF UB-221 FOR CHRONIC SPONTANEOUS URTICARIA TREATMENT MEETS PRIMARY ENDPOINT Source text Further company

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)